European S3‐Guidelines on the systemic treatment of psoriasis vulgaris
Top Cited Papers
Open Access
- 26 August 2009
- journal article
- practice guideline
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 23 (s2), 1-70
- https://doi.org/10.1111/j.1468-3083.2009.03389.x
Abstract
Of the 131 studies on monotherapy or combination therapy assessed, 56 studies on the different forms of phototherapy fulfilled the criteria for inclusion in the guidelines. Approximately three-quarters of all patients treated with phototherapy attained at least a PASI 75 response after 4 to 6 weeks, and clearance was frequently achieved (levels of evidence 2 and 3). Phototherapy represents a safe and very effective treatment option for moderate to severe forms of psoriasis vulgaris. The onset of clinical effects occurs within 2 weeks. Of the unwanted side effects, UV erythema from overexposure is by far the most common and is observed frequently. With repeated or long-term use, the consequences of high, cumulative UV doses (such as premature aging of the skin) must be taken into consideration. In addition, carcinogenic risk is associated with oral PUVA and is probable for local PUVA and UVB. The practicability of the therapy is limited by spatial, financial, human, and time constraints on the part of the physician, as well as by the amount of time required by the patient. From the perspective of the cost-bearing institution, phototherapy has a good cost-benefit ratio. However, the potentially significant costs for, and time required of, the patient must be considereKeywords
This publication has 110 references indexed in Scilit:
- Incidence and Risk Factors for Psoriasis in the General PopulationArchives of Dermatology, 2007
- The Risk of Mortality in Patients With PsoriasisArchives of Dermatology, 2007
- Smoking and the Risk of Psoriasis in Women: Nurses’ Health Study IIThe American Journal of Medicine, 2007
- German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)Archiv für dermatologische Forschung, 2007
- Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasisJournal of the American Academy of Dermatology, 2006
- Relapse, rebound, and psoriasis adverse events: An advisory group reportJournal of the American Academy of Dermatology, 2006
- Acitretin plus UVB therapy for psoriasis: Comparisons with placebo plus UVB and acitretin aloneJournal of the American Academy of Dermatology, 1991
- Side-effect profile of acitretin therapy in psoriasisJournal of the American Academy of Dermatology, 1989
- Acitretin versus etretinate in psoriasis: Clinical and pharmacokinetic results of a German multicenter studyJournal of the American Academy of Dermatology, 1988
- Combined methotrexate-PUVA therapy in the treatment of psoriasisJournal of the American Academy of Dermatology, 1982